1. Signaling Pathways
  2. Epigenetics
  3. Histone Acetyltransferase
  4. HBO1 Isoform

HBO1

HBO1 (histone acetyltransferase binding to ORC1), also known as KAT7/MYST2, is a member of the MYST family of histone acetyltransferases and functions as a major chromatin-modifying enzyme that regulates histone H3 and H4 acetylation, thereby influencing transcription, DNA replication, and genome maintenance[1][2]. Mechanistically, HBO1 operates within multiprotein chromatin complexes containing JADE, ING, and MEAF6 family proteins, where scaffold subunits direct chromatin targeting and histone substrate specificity[3][4]. Through these complexes, HBO1 contributes to chromatin-associated acetylation events that support DNA replication licensing, cell-cycle progression, and gene expression programs[2][4][5]. Studies in epithelial regeneration and kidney injury models further demonstrate that HBO1-associated complexes participate in proliferative responses and correlate with histone H4 acetylation during tissue recovery[6]. Disease-oriented investigations have linked aberrant HBO1 expression or activity to multiple cancer contexts, including osteosarcoma and other solid tumors, supporting its relevance as a regulator of tumor-associated chromatin states[5][7]. Compared with related MYST acetyltransferases, HBO1 is distinguished by its assembly with alternative JADE or BRPF family cofactors, which can alter histone tail specificity and chromatin recruitment mechanisms[3][4]. For experimental applications, the selective small-molecule inhibitor WM-3835 has been used to suppress HBO1-dependent acetylation and proliferation phenotypes, providing a useful tool for mechanistic studies of HBO1-regulated pathways[5].

HBO1 Related Products (2):

Cat. No. Product Name Effect Purity
  • HY-134901
    WM-3835
    Inhibitor 99.78%
    WM-3835 is a potent and high-specific HBO1 (KAT7 or MYST2) inhibitor and binds directly to the acetyl-CoA binding site of HBO1. WM-3835 activates apoptosis while inhibits osteosarcoma (OS) cell proliferation, migration and invasion. WM-3835 has antitumor activity and potently inhibits pOS-1 xenograft growth in mice.
  • HY-177046
    KAT6A/KAT7-IN-4
    Inhibitor 98.86%
    KAT6A/KAT7-IN-4 is a KAT6A and KAT7 inhibitor. KAT6A/KAT7-IN-4 has IC50 values of both ≤ 1 nM for KAT6A and KAT7. KAT6A/KAT7-IN-4 can inhibit the acetylation of H3K14 and H3K23. KAT6A/KAT7-IN-4 also inhibits tumor cell proliferation, with an IC50 of ≤ 100 nM for CAMA-1. KAT6A/KAT7-IN-4 can be used in the study of breast cancer.